Wife of Lot,
I agree that your husband appears to fall in the high risk category and studies have consistently shown that ADT offers cancer-specific survival benefits for persons with high risk localized cancer when used as an adjuvant therapy.
Show him this study
where the findings were:
* Studies of immediate versus deferred ADT without local treatment consistently showed only limited benefit for overall survival and prostate cancer-specific survival.
* Studies of ADT as an adjuvant to radiation therapy in patients with high-risk localized prostate cancer or locally advanced prostate cancer have consistently shown substantial benefit favoring overall and prostate cancer-specific survival.
* Studies of ADT as an adjuvant therapy in patients with proven systemic disease (e.g., node-positive patients after radical prostatectomy) have also consistently shown substantial benefit favoring overall and prostate cancer-specific survival.
* There appears to be a statistically significant and a clinically important survival benefit associated with adjuvant ADT when a local treatment has been applied to the primary tumor.
Age 66, PC diagnosed 7/2009 at age 65
Stage: T2c, Gleason: 9 (4 + 5), 6 of 6 cores positive
Bone, CAT and MIR scans negative
Treatment: brachytherapy (103 palladium), 100 gy, 11/2010 + hormone therapy (Lupron + Casodex) + IMRT on Novalis, 45 gy, 3/2010.
PSA: 7/2009, At time of diagnosis -- 11.9
10/2009 -- 5.0
12/2009 -- 0.56
5/2010 -- 0.15
8/9/2010 -- 0.06
Post Edited (Sancarlos) : 9/4/2010 1:02:20 PM (GMT-6)